Epivir

RSS

lamivudine

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European Public Assessment Report (EPAR) for Epivir. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Epivir.

This EPAR was last updated on 11/07/2019

Authorisation details

Product details
Name
Epivir
Agency product number
EMEA/H/C/000107
Active substance
lamivudine
International non-proprietary name (INN) or common name
lamivudine
Therapeutic area (MeSH)
HIV Infections
Anatomical therapeutic chemical (ATC) code
J05AF05
Publication details
Marketing-authorisation holder
ViiV Healthcare BV
Revision
43
Date of issue of marketing authorisation valid throughout the European Union
08/08/1996
Contact address

Huis ter Heideweg 62
3705 LZ Zeist
The Netherlands

Product information

27/02/2019 Epivir - EMEA/H/C/000107 - IAIN/0110

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Epivir is indicated as part of antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV)-infected adults and children.

Assessment history

How useful was this page?

Add your rating